Nanoparticle-Based Drug Delivery Systems and Targeting Strategies in Breast Cancer Therapy

Abstract

Breast cancer continues to be a major contributor to cancer-related mortality globally, highliting the critical importance of developing more efficient and safer therapy strategies. Nanoparticle-based drug delivery systems offer a promising approach by enhancing drug accumulation in tumor tissues while minimizing systemic toxicity. This article explores the unique properties and advantages of various nanoparticles, including liposomal, polymer-, carbon- and mesoporous silica nanoparticles, in breast cancer therapy. Additionally, it delves into three key targeting mechanisms: passive targeting via the enhanced permeability and retention (EPR) effect, active targeting using ligands and antibodies, and stimuli-responsive drug delivery systems. Integrating nanotechnology into breast cancer therapy paves the way for more precise, efficient, and personalized therapy options, offering new hope for improved patient outcomes.

Keywords

• Breast Cancer
• Drug Delivery Systems
• Nanoparticle

Meme Kanseri Tedavisinde Nanopartikül Tabanlı İlaç Taşıma Sistemleri ve Hedefleme Stratejileri

Abstract

Breast cancer continues to be a major contributor to cancer-related mortality globally, highlighting the critical importance of developing more efficient and safer therapy strategies. Nanoparticle-based drug delivery systems offer a promising approach by enhancing drug accumulation in tumor tissues while minimizing systemic toxicity. This article explores the unique properties and advantages of various nanoparticles, including liposomal, polymer-, metal-, carbon- and mesoporous silica nanoparticles, in breast cancer therapy. Additionally, it delves into three key targeting mechanisms: passive targeting via the enhanced permeability and retention (EPR) effect, active targeting using ligands and antibodies, and stimuli-responsive drug delivery systems. Integrating nanotechnology into breast cancer therapy paves the way for more precise, efficient, and personalized therapy options, offering new hope for improved patient outcomes. Keywords: Breast Cance

Keywords

• Meme Kanseri
• İlaç Dağıtım Sistemleri
• Nanopartikül

References

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
2. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654
3. DeSantis, C. E., et al. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583
4. Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A. (2017). Global cancer in women: Burden and trends. Cancer Epidemiology, Biomarkers & Prevention, 26(4), 444–457. https://doi.org/10.1158/1055-9965.EPI-16-0858
5. Lehmann, B. D., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation, 121(7), 2750–2767. https://doi.org/10.1172/jci45014
6. Sørlie, T., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences, 98(19), 10869–10874. https://doi.org/10.1073/pnas.191367098
7. Slamon, D. J., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783–792. https://doi.org/10.1056/nejm200103153441101
8. Mavaddat, N., et al. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. American Journal of Human Genetics, 104(1), 21–34. https://doi.org/10.1016/j.ajhg.2018.11.002

9. Cardoso, F., et al. (2019). Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
10. Stehr, M., Deilmann, K., Haas, R. J., & Dietz, H. G. (2005). Surgical complications in the treatment of Wilms’ tumor. European Journal of Pediatric Surgery, 15(6), 414–419. https://doi.org/10.1055/s-2005-872915
11. Chaudhari, R., Patel, V., & Kumar, A. (2024). Cutting-edge approaches for targeted drug delivery in breast cancer: Beyond conventional therapies. Nanoscale. https://doi.org/10.1039/d4na00086b
12. Darby, S., et al. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. The Lancet, 378(9804), 1707–1716. https://doi.org/10.1016/s0140-6736(11)61629-2
13. Emens, L. A. (2018). Breast cancer immunotherapy: Facts and hopes. Clinical Cancer Research, 24(3), 511–520. https://doi.org/10.1158/1078-0432.ccr-16-3001
14. Prat, A., et al. (2013). Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist, 18(2), 123–133. https://doi.org/10.1634/theoncologist.2012-0397
15. Manzari, M. T., et al. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351–370. https://doi.org/10.1038/s41578-020-00269-6
16. Rosenblum, D., et al. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-03705-y
17. Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387
18. Fang, J., Nakamura, H., & Maeda, H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews, 63(3), 136–151. https://doi.org/10.1016/j.addr.2010.04.009
19. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63(3), 131–135. https://doi.org/10.1016/j.addr.2010.03.011
20. Boman, N. L., et al. (1998). Liposomal vincristine: The central role of drug retention in defining therapeutically optimized anticancer formulations. In Long Circulating Liposomes: Old Drugs, New Therapeutics (pp. 29–49). https://doi.org/10.1007/978-3-662-22115-0_3
21. Vahed, S. Z., et al. (2021). Mesoporous silica nanoparticles for smart delivery of therapeutics: A comprehensive review of safety, toxicity, and biodegradation. Journal of Controlled Release, 337, 1–27. https://doi.org/10.1016/j.jconrel.2021.07.016
22. Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 47(2–3), 165–196. https://doi.org/10.1016/s0169-409x(01)00105-3
23. Shi, J., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108
24. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330
25. Bai, Y., et al. (2020). MOF-mediated delivery of nanosized paclitaxel to improve the antitumor effect in vivo. Journal of Materials Chemistry B, 8(15), 3250–3257. https://doi.org/10.1039/d0tb00363d
26. Xu, X., et al. (2020). Co-delivery of paclitaxel and curcumin by PEGylated liposomes to improve anti-breast cancer treatment. International Journal of Nanomedicine, 15, 6349–6362. https://doi.org/10.2147/ijn.s253759
27. Wang, Y., et al. (2020). Recent advances in the development of polymeric micelles for the treatment of breast cancer. Nanomedicine, 15(10), 941–957. https://doi.org/10.2217/nnm-2020-0029
28. Zhao, Y., et al. (2020). Targeted co-delivery of doxorubicin and paclitaxel by folic acid-modified lipid-polymer hybrid nanoparticles for breast cancer treatment. International Journal of Nanomedicine, 15, 3583–3596. https://doi.org/10.2147/ijn.s241050
29. Maeda, H., & Khatami, M. (2018). Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clinical and Translational Medicine, 7(1), 11. https://doi.org/10.1186/s40169-018-0185-6
30. Jiang, Y., et al. (2019). Single-particle tracking reveals that binding kinetics of nanocarriers to the cell membrane modulates their transport behavior. Nature Nanotechnology, 14(9), 874–882. https://doi.org/10.1038/s41565-019-0490-y
31. Li, S. Y., et al. (2016). Self-assembled cRGD–polyethylene glycol–paclitaxel micelles for targeted therapy of triple-negative breast cancer. Molecular Pharmaceutics, 13(9), 3152–3160. https://doi.org/10.1021/acs.molpharmaceut.6b00412